Currently, there are 144.34M common shares owned by the public and among those 134.04M shares have been available to trade.
The company’s stock has a 5-day price change of -10.40% and 6.53% over the past three months. IONS shares are trading -16.21% year to date (YTD), with the 12-month market performance up to 2.86% higher. It has a 12-month low price of $35.95 and touched a high of $54.44 over the same period. IONS has an average intraday trading volume of 1.32 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -10.93%, -11.74%, and -7.76% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Ionis Pharmaceuticals Inc (NASDAQ: IONS) shares accounts for 97.10% of the company’s 144.34M shares outstanding.
It has a market capitalization of $6.20B and a beta (3y monthly) value of 0.38. The earnings-per-share (ttm) stands at -$2.53. Price movements for the stock have been influenced by the stock’s volatility, which stands at 4.20% over the week and 3.13% over the month.
Earnings per share for the fiscal year are expected to decrease by -40.44%, and 4.88% over the next financial year.
Looking at the support for the IONS, a number of firms have released research notes about the stock. BMO Capital Markets stated their Market Perform rating for the stock in a research note on August 02, 2024, with the firm’s price target at $67-$60. Leerink Partners coverage for the Ionis Pharmaceuticals Inc (IONS) stock in a research note released on July 24, 2024 offered a Outperform rating with a price target of $62. Jefferies was of a view on July 16, 2024 that the stock is Buy, while Bernstein gave the stock Mkt Perform rating on June 14, 2024, issuing a price target of $44. Wolfe Research on their part issued Outperform rating on April 10, 2024.
